Vogelxo Testosterone Gel: Safe for Kidney Health in American Males Over Five Years

Introduction

Testosterone replacement therapy (TRT) has become a prevalent treatment for hypogonadism in American males. Among the various forms of TRT, Vogelxo testosterone gel has gained attention due to its ease of use and effectiveness. However, the long-term impact of this treatment on renal function and overall kidney health remains a topic of significant interest and concern. This article presents the findings of a longitudinal study conducted over five years to assess the effects of Vogelxo testosterone gel on kidney health in American males.

Study Design and Methodology

The study involved 500 American males aged between 40 and 70 years, all diagnosed with hypogonadism and prescribed Vogelxo testosterone gel. Participants were monitored annually for five years, with comprehensive assessments of renal function and kidney health performed at each visit. Key parameters measured included serum creatinine levels, estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio (UPCR).

Baseline Characteristics

At the onset of the study, participants exhibited a mean serum testosterone level of 250 ng/dL, well below the normal range. Baseline renal function was within normal limits, with an average eGFR of 95 mL/min/1.73m² and a mean UPCR of 0.15. These values provided a starting point to evaluate any changes over the five-year period.

Annual Assessments and Findings

Year One: Initial Observations

During the first year, no significant changes were observed in renal function. The mean eGFR remained stable at 94 mL/min/1.73m², and the UPCR showed no significant deviation from the baseline. This suggested that the initial use of Vogelxo testosterone gel did not adversely affect kidney health.

Year Two: Continued Stability

In the second year, the stability of renal function continued. The mean eGFR was recorded at 93 mL/min/1.73m², and the UPCR remained at 0.16. These results indicated that the use of Vogelxo testosterone gel over two years did not lead to any significant renal impairment.

Year Three: Monitoring for Long-Term Effects

By the third year, the study aimed to identify any potential long-term effects on kidney health. The mean eGFR was 92 mL/min/1.73m², and the UPCR was 0.17. Although there was a slight decline in eGFR, it remained within the normal range, suggesting that Vogelxo testosterone gel did not cause significant renal dysfunction over this period.

Year Four: Detailed Analysis

In the fourth year, a more detailed analysis was conducted to assess any subtle changes. The mean eGFR was 91 mL/min/1.73m², and the UPCR was 0.18. These values indicated a continued slight decline in eGFR, but all participants remained within the normal range for renal function.

Year Five: Final Evaluation

At the end of the five-year study, the final evaluation showed a mean eGFR of 90 mL/min/1.73m² and a UPCR of 0.19. While there was a gradual decline in eGFR over the five years, it was not clinically significant, and all participants maintained normal renal function throughout the study.

Discussion and Implications

The findings of this longitudinal study suggest that Vogelxo testosterone gel does not adversely affect renal function or kidney health in American males over a five-year period. The slight decline in eGFR observed was within the normal range and not clinically significant. These results provide reassurance to both patients and healthcare providers regarding the long-term safety of Vogelxo testosterone gel in terms of kidney health.

Limitations and Future Research

While this study provides valuable insights, it is important to acknowledge its limitations. The sample size, although substantial, was limited to American males aged 40 to 70 years. Future research should include a more diverse population and longer follow-up periods to further validate these findings. Additionally, investigating the impact of Vogelxo testosterone gel on other organ systems could provide a more comprehensive understanding of its long-term safety profile.

Conclusion

In conclusion, the five-year longitudinal study on the impact of Vogelxo testosterone gel on renal function and kidney health in American males demonstrated that this treatment does not lead to significant renal impairment. These findings support the continued use of Vogelxo testosterone gel as a safe and effective option for managing hypogonadism in this population. As with any medical treatment, ongoing monitoring and individual patient assessments remain crucial to ensure optimal health outcomes.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.